

Available online on 15.04.2019 at <http://jddtonline.info>

# Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Review Article

## BRCA mutation: A review of breast cancer

R. Margret Chandira\*, M. Prabakaran, B. Jaykar, B.S. Venkateswarlu and P. Palanisamy

Department of Pharmaceutics, Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation (Deemed to be University), Salem (D.T), Tamil Nadu (State), India.

### ABSTRACT

In the present study, we focus on the causes of a major cancer type contributing to the major deaths due to cancer across the world. Breast cancer which accounts for more than approximately 29 to 34% affected to women posing a major cause of death due to cancer. In-situ carcinomas might arise in either ductal or lobular epithelium, but remain confined there, with no invasion of the underlying basement membrane that would constitute extension beyond epithelial boundaries. Approximately 29 to 34% of women with invasive breast cancer will die of their disease. This syndrome presents as skin changes resembling skin condition like redness, discoloration, or mild flaking of the nipple skin. As Paget's disease of the breast advances, symptoms may include skin tingling, itching, increased sensitivity, burning and pain. There may also be discharge from the nipple. Approximately half of women diagnosed with Paget's disease of the breast even have a lump within the breast.

**Keywords:** Breast cancer, BRCA mutation, BRCA1, BRCA2.

**Article Info:** Received 21 Feb 2019; Review Completed 29 March 2019; Accepted 02 April 2019; Available online 15 April 2019



### Cite this article as:

Margret Chandira R, Prabakaran M, Jaykar B, Venkateswarlu BS, Palanisamy P, BRCA mutation: A review of breast cancer, Journal of Drug Delivery and Therapeutics. 2019; 9(2-s):617-624 <http://dx.doi.org/10.22270/jddt.v9i2-s.2507>

### \*Address for Correspondence:

R. Margret Chandira\*, M.Pharm., Ph.D., Department of Pharmaceutics, Vinayaka Mission's College of Pharmacy, Yercaud Main Road, Kondappanaickenpatty, Salem (D.T), Tamil Nadu (State), Pin. Code: 636 008.

### INTRODUCTION

Cancer is a group of disease involved in abnormal growth of cell with the potential spread to other parts of the body.<sup>1,2</sup> Cancer when develops to normal cells in a particular part of the body begin to grow out of control. Cardio vascular disease is the first leading cause of death in the world and Cancer is the second leading cause of death in the world. Generally cancer cells are developed from normal cells due to damage of DNA. Most of the time when ever DNA was damaged, the body is able to repair it, unfortunately in cancer cells, damaged DNA is not repaired. People can also inherit damaged DNA from parents, which accounts for inherited cancers.<sup>3</sup>

#### Breast cancer:

It is type of Cancer that forms in tissues of the breast. It occurs in both men and women, although male breast cancer is rare than female breast cancer. Breast cancer commonly develops in lining of milk duct cells and the lobules that supply the ducts with milk. Cancers developing from the ducts are known as ductal carcinomas. Although the cancers developing from lobules are known as lobular carcinomas.<sup>4,5</sup> Breast cancers are divided into two major types, in-situ carcinomas and invasive(or infiltrating) carcinomas. The in-situ type of carcinomas may arise in ductal or lobular epithelium, but remain confined there, with no invasion of

the underlying basement membrane that would constitute extension beyond epithelial boundaries.<sup>6</sup> Approximately 29% to 34% of women with invasive breast cancer will die of their disease.<sup>7</sup>

#### Signs and symptoms:

Signs of breast cancer may include a tumor in the breast, mutation in breast, dimpling of the skin, fluid coming from the breast nipple, a newly inverted nipple, or a red patch of skin. Inflammatory breast cancer is a one type of breast cancer which can pose a actual diagnostic challenge. Symptoms may resemble a inflammation in breast and may include pain, itching, nipple inversion, swelling, warmth and redness throughout the breast, as well as an orange-peel texture to the skin referred to as peau d'orange.<sup>8</sup> Another reported symptom complex of breast cancer is Paget's disease of the breast. This syndrome presents as skin redness, discoloration or mild flaking of the nipple skin. As Paget's disease of the breast advances, symptoms may include burning, itching, enhanced the sensitivity, tingling, and pain. Approximately half of women's are diagnosed with Paget's disease of the breast also has a tumor in the breast.<sup>9</sup>

In rare cases, what initially appears as a fibroadenoma (hard, movable non-cancer lump) could in fact be a phyllodes tumor. Phyllodes tumors are formed within the connective tissue of the breast and contain glandular as well as stromal

tissue. Phyllode breast lumps are not staged in the usual sense; they are classified depends on their appearance under the microscope as benign, borderline, or malignant.<sup>10</sup> Occasionally, breast cancer presents as metastatic disease that is, cancer that has spread away the original organ. The symptoms caused by metastatic breast cancer depend on the location of metastasis. Common sites of metastasis include bone, liver, lung and brain.<sup>11</sup>

#### Causes of breast cancer:

**Genetic causes;** Family history has long been known to be a risk factor for breast carcinoma. Both maternal and paternal relatives are important. The risk is highest if the affected relative developed breast carcinoma at a young age, had carcinoma in both breasts or if she is a close relative. First-degree relatives, (mother, sister, daughter) are most vital in estimating risk. Some second-degree relatives (grandmother, aunt) with breast cancer may increase risk. Breast cancer in a male increases the risk for all his close female relatives. BRCA1 and BRCA2 are abnormal genes that, when inherited, markedly increase the risk of breast cancer to a lifetime risk estimated between 40 and 85%. Women who have the BRCA1 gene tend to develop breast cancer at an early age.<sup>12</sup>

**Hormonal causes;** Alteration in hormonal level may precipitate breast cancer. It could be attended by starting and stopping of periods (Menstrual Cycle), Pregnancy in early age, Hormonal replacement therapy, Use of oral pills, etc.<sup>13</sup>

**Life style and dietary cause;** Sedentary life style, high dietary intake of fat obesity particularly in postmenopausal women may cause breast cancer. The use of alcohol is also another one cause of breast cancer. The risk increases with the amount of alcohol consumed. Women who consume two to five alcoholic beverages per day have a risk about one and a half times that of nondrinkers for the development of breast cancer.<sup>14,15</sup>

**Environmental cause;** There is known to be a slight increase in risk in ladies who work with low doses of radiation over a long period of time-for example, X-ray technicians.<sup>14,15</sup>

#### Pathophysiology:

Breast cancer, like other cancers occurs because of an interaction between an environmental (external) factor and a genetically susceptible host. Mutations that can lead to breast cancer have been experimentally linked to estrogen exposure.<sup>16</sup> Abnormal growth factor signaling in the interaction between stromal cells and epithelial cells can facilitate malignant cell growth.<sup>17,18</sup> In breast adipose tissue, over expression of leptin leads to increased cell proliferation and cancer.<sup>19</sup>

In the United States, 10% to 20% of people with breast cancer and ovarian cancer have a first- or second-degree relative with one of these diseases. The familial tendency to developed cancer is called hereditary breast-ovarian cancer syndrome. The best known of these, the BRCA mutations, confer a lifetime risk of breast cancer of between 60% and 85% and a lifetime risk of ovarian cancer of between 15 and 40 percent. Some mutations associated with cancer, such as BRCA1 and BRCA2, occur in mechanisms to correct errors in DNA. These mutations are either inherited or acquired after birth. Presumably, they allow further mutations, which allow uncontrolled division, lack of attachment, and metastasis to distant organs.<sup>20</sup> However, there is strong evidence of residual risk variation that goes well beyond hereditary BRCA gene mutations between carrier families.

This is caused by unobserved risk factors.<sup>21</sup> This implicates environmental and other causes as triggers for breast cancers. The inherited mutation in BRCA1 or BRCA2 genes can interfere with repair of DNA cross links and DNA double strand breaks (known functions of the encoded protein).<sup>22</sup> These carcinogens cause DNA damage such as DNA cross links and double strand breaks that often require repairs by pathways containing BRCA1 and BRCA2.<sup>23,24</sup> Focus of this present review is to study about the breast cancer by gene mutations.

#### MATERIAL AND METHODS

Initially, we searched papers using keywords like breast cancer, gene mutation, genetic causes and BRCA. Subsequently the papers are matched such word criteria were fully reviewed and their findings duly noted.

#### BRCA Mutation:

A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, these are tumor suppressor genes. Different types of mutations in these genes have been identified, some of these determined to be harmful, while others have no proven impact. Harmful mutations in these genes may produce a hereditary breast cancer syndrome in affected persons. Breast cancer cases in women Only 5-10% are reason to BRCA1 and BRCA2 mutations (with BRCA1 mutations being slightly more than BRCA2 mutations), but the impact on women with the gene mutation is more profound.<sup>25</sup> Women with harmful mutations in either BRCA1 or BRCA2 have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal.<sup>26</sup>

Mutations can be inherited from either parent and may be passed through on to both sons and daughters. Each child of a genetic carrier, not regard to sex, has a 50% chance of inheriting the mutated gene from the parent who carries the mutation. As a result, half of the people with BRCA gene mutations are male, who would then pass the mutation on to 50% of their offspring, male or female. The risk of BRCA-related breast cancers for men with the mutation is higher than for other men, but still low.<sup>27</sup>

The BRCA1 and BRCA2 genes are tumor suppressor genes pictured here on their respective chromosomes. BRCA1 has located in 17q21 or the q arm of Chromosome 17 at position 21. BRCA2 has located in 13q12.3 or the q arm of Chromosome 13 at position 12.3. Both BRCA1 and BRCA2 genes are produce proteins that help repair damaged DNA, keeping the genetic material of the cell stable. A damaged BRCA gene in either location can lead to increase the risk of cancer, particularly breast or ovarian in women.





Fig. 1: Location of BRCA Gene

**Survival impact:** <sup>28</sup>

**Figure 2: Likelihood of a 25-year-old woman surviving to age 70**

A 25-year-old woman with no mutation in her BRCA genes has an 84% probability to reach at least the age of 70. Of those not surviving, eleven percentages die from either breast or ovarian cancer, and 89% from other cancers. Compared to that, a woman with a high-risk BRCA1 mutation, if she had carcinomas in breast tissues screening but no prophylactic medical or surgical intervention, would have only fifty nine percentage chances to reach age 70, twenty five percentage points lower than normal. Of those women not surviving, twenty six percentages would die of breast cancer, forty six percentage of ovarian cancer and twenty eight percentages of other causes.

Women with high-risk BRCA2 mutations, with screening but with no prophylactic medical or surgical intervention, would have only seventy one percentage chance to reach age 70, thirteen percentage points lower than normal. Of those not surviving twenty one percentages would die of breast cancer, twenty five percentage of ovarian cancer and fifty four percentages of other causes. The likelihood of surviving to minimum age 70 can be improved by several medical interventions, notably prophylactic mastectomy and oophorectomy.

#### Childbearing and fertility effects:

The dilemma of whether or not to have children is a significant source of stress for women who learn of their BRCA mutations during their childbearing years.<sup>29</sup> There is likely little or no effect of a BRCA gene mutation on overall fertility,<sup>30</sup> although women with a BRCA mutation may be more likely to have primary ovarian insufficiency.<sup>31,32</sup> BRCA mutation carriers may be more likely to give birth to girls than boys,<sup>33</sup> however this observation has been attributed to ascertainment bias.<sup>34,35</sup> If both parents are carriers of a BRCA mutation, then pre-implantation genetic diagnosis is sometimes used to prevent the birth of a child with BRCA mutations. Inheriting two BRCA1 mutations (one from parent) has never been reported and is believed to be a lethal birth defect. Inheriting one BRCA1 mutation and one BRCA2 mutation have been reported occasionally; the child's risk for any given type of cancer is the higher risk of the two genes like BRCA1 and BRCA2. (e.g., the risk of ovarian cancer from BRCA1 gene and the risk of pancreatic cancer from BRCA2 gene). Inheriting two BRCA2 mutations produces Fanconi anemia. <sup>[36]:82-85</sup>

Each pregnancy in genetically typical women is associated with a significant reduction in the mother's risk of developing carcinomas in breast tissues after age of

40.<sup>29</sup> The young woman is at the time of her first birth and the more protection against breast cancer she receives. Breastfeeding for more than one year protects against breast cancer.<sup>36</sup> Pregnancy also protects against ovarian cancer in genetically typical women.<sup>29</sup>

Although some studies have produced different results, women with BRCA mutations are generally not expected to receive these significant protective benefits.<sup>36</sup> Current research is too limited and imprecise to permit calculation of specific risks.<sup>29</sup>

However, the following general trends have been identified:

- For women with a BRCA1 mutation, the woman's age when she first gives birth has no association with her risk of breast cancer. Childbearing provides no protection against breast cancer, unless the woman has five or more than five full-term pregnancies, at which point she receives only modest protection. Similar to genetically typical women, pregnancy protects against ovarian cancer in BRCA1 gene women. Breastfeeding for more than one year considerably protects against breast cancer.<sup>29</sup> This effect may be as high as 19% per year of breastfeeding, which is much higher than that seen among genetically typical women.<sup>37</sup> The effect, if any, of long-term breastfeeding on ovarian cancer is unclear.<sup>29</sup>
- For women with a BRCA2 mutation, each pregnancy is paradoxically associated with a statistically significant increase in the risk for breast cancer. Unlike genetically typical women or women with BRCA1 gene mutations, breastfeeding has no effect on either cancer in women with BRCA2 gene mutations. Limited and conflicting data suggest that, also unlike other women, pregnancy does not decrease the ovarian cancer risk significantly in women with a BRCA2 gene mutation and might increase it.<sup>29</sup>

#### BRCA1:

Breast cancer type 1 susceptibility protein is a protein that in humans is encoded by the BRCA1 gene.<sup>38</sup> Orthologs are most common in other mammalian species.<sup>39</sup> BRCA1 is a human tumor suppressor gene<sup>40, 41</sup> (also known as a caretaker gene) and is responsible for repairing DNA.<sup>42</sup> BRCA1 combines with other tumor suppressors, DNA damage sensors and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC).<sup>43</sup> The BRCA1 protein associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. The role of this protein is transcription, and DNA repair of double-strand DNA breaks<sup>44</sup> ubiquitination, transcriptional regulation as well as other functions.<sup>45</sup>

BRCA1 has 24 exons, including 2 non-translating exons, encoding a protein of 1863 amino acids, which is characterized by a zinc-binding RING finger domain at the amino terminus and BRCA1 carboxyl-terminal (BRCT) domain at the carboxyl terminus. BRCA1 is classified as a tumor suppressor gene and plays an important role in surveillance of cell cycle and repair of DNA damage. Evidence shows that BRCA1 is phosphorylated by the check point kinase ataxia telangiectasia mutated (ATM) protein after ionizing radiation.<sup>46</sup>

#### Gene location:

The human BRCA1 gene is located on the long (q) arm of chromosome 17 at region 2 band 1, from base pair 41,196,312 to base pair 41,277,500 (Build GRCh37/hg19) <sup>47</sup>




Fig. 3: BRCA1 Gene location (Human)

### Mutations and Cancer risk:

Certain variations of the BRCA1 gene lead to an increased risk for breast cancer as part of a hereditary breast and ovarian cancer symptoms. Researchers have identified more than hundred mutations in the BRCA1 gene, many of which are associated with an increased risk of cancer. Females with an abnormal BRCA1 or BRCA2 genes have up to an 80% risk of developing carcinomas in breast tissues by age 90; increased risk of developing ovarian cancer is about 55% for females with BRCA1 mutations and about 25% for females with BRCA2 mutations.<sup>48</sup>

These mutations can be changes in a small number of DNA base pairs (the building-blocks of DNA), and can be identified with PCR and DNA sequencing. Some cases large segments of DNAs are rearranged. Those large segments, also called large rearrangements, can be a deletion of one or several exons in the gene. Classical methods for mutation detection (sequencing) are unable to reveal these types of mutation.<sup>49</sup> Other methods have been proposed: traditional quantitative PCR,<sup>50</sup> Multiplex Ligation-dependent Probe Amplification (MLPA),<sup>51</sup> and Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF).<sup>52</sup> Newer methods have also been recently proposed: hetero-duplex analysis (HDA) by multi-capillary electrophoresis or also dedicated oligo-nucleotides array based on comparative genomic hybridization (array-CGH).<sup>53</sup> Some results suggest that hyper-methylation of the BRCA1 promoter, which has been reported in some cancers, could be considered as an inactivating mechanism for BRCA1 expression.<sup>54</sup>

BRCA1 mRNA 3' UTR can be bound by an miRNA, Mir-17 microRNA. It has been suggested that variations in this miRNA along with Mir-30 microRNA could confer susceptibility to breast cancer.<sup>55</sup> In addition to breast cancer, mutations in the BRCA1 gene also increase the risk of ovarian and prostate cancers. Moreover, precancerous lesions (dysplasia) within the Fallopian tube have been linked to BRCA1 mutations. Pathogenic mutations anywhere in a model pathway containing BRCA1 and BRCA2 greatly increase risks for a subset of leukemias and lymphomas.<sup>44</sup>

Females who have inherited a defective BRCA1 or BRCA2 gene are greatly elevated risk to develop breast and ovarian cancer. Their risk of developing breast and ovarian cancer is high, and specific to those cancers, that many mutation

carriers choose to have prophylactic surgery. There has been more conjecture to explain such apparently striking tissue specificity. Major determinants of where BRCA1 and BRCA2 hereditary cancers occur are associated to tissue specificity of the cancer pathogen, the agent that causes chronic inflammation or the carcinogen. The target tissue may having the receptors for the pathogen, may become selectively exposed to an inflammatory process or carcinogen. An innate genomic deficit in a tumor suppressor gene impairs normal responses and exacerbates the susceptibility to disease in organ targets. This theory also fits data for several tumor suppressors beyond BRCA1 or BRCA2 genes. A major advantage of this model is that it suggests there may be some options in addition to prophylactic surgery.<sup>56</sup>

### Low expression of BRCA1 in breast and ovarian cancers:

BRCA1 expression is reduced or undetectable in the majority of high grade, ductal breast cancers.<sup>57</sup> It has long been noted that loss of BRCA1 activity, either by germ-line mutations or by down-regulation of gene expression, leads to tumor formation in specific target tissues. In particular, decreased BRCA1 expression contributes to both sporadic and inherited breast tumor progression.<sup>58</sup> Reduced expression of BRCA1 is tumorigenic because it plays an important role in the repair of DNA damages, especially double-strand breaks, by the potentially error-free pathway of homologous recombination. Since cells that lack the BRCA1 protein tend to repair DNA damages by alternative more error-prone mechanisms, the reduction or silencing of this protein generates mutations and gross chromosomal rearrangements that can lead to progression to breast cancer.<sup>59</sup>

Similarly BRCA1 gene expression is low in the majority (55%) of sporadic epithelial ovarian cancers (EOCs) wherever EOCs are the common ovarian type of cancer, representing approximately 90% of ovarian cancers.<sup>60</sup> In serous ovarian carcinomas, a sub-category constituting about 2/3 of EOCs, low BRCA1 expression occurs in more than 50% of cases.<sup>61</sup>

### Mutation of BRCA1 in breast and ovarian cancer:

Only about 3%–8% of all women with breast cancer carry a mutation in BRCA1 or BRCA2.<sup>62</sup> Similarly, BRCA1 mutations

are only seen in about 18% of ovarian cancers (13% germline mutations and 5% somatic mutations).<sup>63</sup> Thus, while BRCA1 expression is low in the majority of these cancers, BRCA1 mutation is not a major cause of reduced expression.

#### BRCA1 promoter hypermethylation in breast and ovarian cancer:

BRCA1 promoter hypermethylation was present in only 13% of unselected primary breast carcinomas.<sup>64</sup> Similarly, BRCA1 promoter hypermethylation was present in only 5% to 15% of EOC cases.<sup>60</sup> Thus, while BRCA1 expression is low in these cancers, BRCA1 promoter methylation is only a minor cause of reduced expression.

#### BRCA2:

BRCA2 are a human gene, it is made up of proteins, respectively. The official symbol (BRCA2, italic for the gene, non-italic for the protein) and the official name (originally breast cancer 2; currently BRCA2, DNA repair associated) are maintained by the HUGO Gene Nomenclature Committee (HGNC). One alternative symbol, FANCD1,

recognizes its association with the FANCD1 protein complex. Orthologs, styled BRCA2 gene and BRCA2 gene are common in other mammalian species.<sup>65</sup> BRCA2 gene covers about 70kb of genomic sequence in 13q12, encoding a protein of 3418 amino acids. The coding region of BRCA2 is composed of 27 exons with a non-translating exon. However, the gene sequence of BRCA2 bears no obvious homology to any known gene including BRCA1, and the protein contains no defined functional domains.<sup>66</sup> BRCA2 can bind with BRCA1, participating in DNA damage response pathway associated with the activation of homologous recombination and double-strand break repair.<sup>67</sup> BRCA2 associated breast carcinomas are rarely that "basal-like" phenotype, but a subtype that has higher grade (usually Grade 2/3) than sporadic age-matched controls (Breast Cancer Linkage Consortium, 1997), and tend to be ER and progesterone receptor (PR) positive.<sup>68</sup>

#### Gene location:

The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3).<sup>69</sup>




Figure 4: BRCA2 Gene location (Human)

#### Function:

Although the structures of the BRCA1 and BRCA2 genes are very different, at least some functions are interconnected. The proteins made by both genes are essential for repairing damaged DNA (see Fig. 5 of recombinational repair steps). BRCA2 binds the single strand DNA and directly interacts with the recombinase RAD51 to stimulate strand invasion, a vital step of homologous recombination. The localization of RAD51 to the DNA double-strand break needs to the formation of the BRCA1-PALB2-BRCA2 complex. Function of PALB2 (Partner and localizer of BRCA2)<sup>70</sup> can synergistically with a BRCA2 chimera (termed piccolo, or piBRCA2) to further promote strand invasion.<sup>71</sup> These breaks can be caused by natural and medical radiation or any other environmental exposures, but also occur when chromosomes exchange genetic material during a special type of cell division that creates sperm and eggs (meiosis). Double strand breaks are also generated during repair of deoxyribonucleic acid (DNA) cross links. By repairing DNA, these proteins play a role in maintaining the stability of the human genome and prevent dangerous gene

rearrangements that can lead to hematologic and other cancers. BRCA2 has been shown to possess a crucial role in protection from the MRE11-dependent nucleolytic degradation of the reversed forks that are forming during DNA replication fork stalling (caused by obstacles such as mutations, intercalating agents etc.).<sup>72</sup>

#### BRCA2 expression in cancer:

In eukaryotes, BRCA2 protein has a very important role in homologous recombinational repair. In humans and mice, BRCA2 genes are primarily mediates orderly assembly of RAD51 on single-stranded DNA, the form that is active for homologous pairing and strand invasion. BRCA2 also redirects RAD51 from double-stranded DNA and prevents dissociation from single-stranded DNA.<sup>73</sup>

In addition, the four paralogs of RAD51, consisting of RAD51B (RAD51L1), RAD51C (RAD51L2), RAD51D (RAD51L3), XRCC2 form a complex called the BCDX2 complex (see Figure 5: Recombinational repair of DNA). This complex participates in RAD51 recruitment or stabilization at damage sites.<sup>74</sup>




Figure 5: Recombinational repair of DNA

The BCDX2 complex appears to act by facilitating the assembly or stability of the RAD51 nucleoprotein filament. RAD51 catalyses strand transfer between a broken sequence and its undamaged homologue to allow re-synthesis of the broken region.

Many cancers have epigenetic deficiencies in various DNA repair genes (see Frequencies of epimutations in DNA repair

genes in cancers). These repair deficiencies likely cause raised unrepaired DNA damages. The over-expression of BRCA2 seen in many cancers may reflect compensatory BRCA2 over-expression and increased homologous recombinational repair to at least partially deal with such excess DNA damages.<sup>75</sup>

Table 1: Germline mutations and founder effect of BRCA1 and BRCA2<sup>76,77</sup>

| Population or subgroup | BRCA1 mutations                                      | BRCA1 mutations                 |
|------------------------|------------------------------------------------------|---------------------------------|
| African-Americans      | 943ins10, M1775R                                     | -                               |
| Afrikaners             | E881X                                                | -                               |
| Ashkenazi Jewish       | 185delAG, 188del11, 5382insC                         | 6174delT                        |
| Austrians              | 2795delA, C61G, 5382insC, Q1806stop                  | -                               |
| Belgians               | 2804delAA, IVS5+3A>G                                 | -                               |
| Dutch                  | Exon 2 deletion, exon 13 deletion, 2804delAA         | 5579insA                        |
| Finns                  | 3745delT, IVS11-2A>G                                 | 8555T>G, 999del5, IVS23-2A>G    |
| French                 | 3600del11, G1710X                                    | -                               |
| French Canadians       | C4446T                                               | 8765delAG, 3398delAAAAG         |
| Germans                | 5382insC, 4184del4                                   | -                               |
| Greeks                 | 5382insC                                             | -                               |
| Hungarians             | 300T>G, 5382insC, 185delAG                           | 9326insA                        |
| Icelanders             | -                                                    | 999del5                         |
| Italians               | 5083del19                                            | 8765delAG                       |
| Japanese               | L63X, Q934X                                          | -                               |
| Native North Americans | 1510insG, 1506A>G                                    | -                               |
| Northern Irish         | 2800delAA                                            | 6503delTT                       |
| Norwegians             | 816delGT, 1135insA, 1675delA, 3347delAG              | -                               |
| Pakistanis             | 2080insA, 3889delAG, 4184del4, 4284delAG, IVS14-1A>G | 3337C>T                         |
| Polish                 | 300T>G, 5382insC, C61G, 4153delA                     | -                               |
| Russians               | 5382insC, 4153delA                                   | -                               |
| Scottish               | 2800delAA                                            | 6503delTT                       |
| Slovenians             | -                                                    | IVS16-2A>G                      |
| Spanish                | R71G                                                 | 3034delAAAC(codon936), 9254del5 |
| Swedish                | Q563X, 3171ins5, 1201del11, 2594delC                 | 4486delG                        |

## CONCLUSION

The review study presented in this article details about the breast cancer which accounts majorly for more than ~29-34%, of death cases amongst the women population. Mostly the gene mutation breast cancer is affected in women. BRCA1 gene mutation breast cancer is more affected than BRCA2. This BRCA2 gene mutation is not common but can be higher in specific populations.

## Author's Contribution

Dr.B.Jayakar reporting preparation of review article, Prof.Dr.B.S.Venakateswarlu & Prof.Dr.R.Margret Chandira supervised the manuscript preparation and reviewed the manuscript.

## Conflicts of Interest

The authors declare no conflicts of interest.

## REFERENCES

1. "Cancer Fact sheet N 297". World Health Organization. February 2018. Retrieved 21 March 2018.
2. "Defining Cancer". National Cancer Institute. 17 September 2007. Retrieved 28 March 2018.
3. Sudhakar A, History of Cancer: Ancient and Modern Treatment Methods, *Journal of Cancer Science & Therapy*, 2009; 1(2). doi:10.4172/1948-5956.100000e2.
4. "Breast Cancer Treatment (PDQ®)". NCI. 23 May 2014. Archived from the original on 5 July 2014. Retrieved 29 June 2014.
5. World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.2. ISBN 978-92-832-0429-9.
6. Rodney C, Breast cancer: A Review of the literature, *Journal of Insurance Medicine*, 2003; 35(2):85-101
7. Harris J, Lippman M, Veronesi U, et al. Breast Cancer (3 parts), *N Engl J Med*, 1992; 327(5):319-328
8. Merck Manual of Diagnosis and Therapy (February 2003). "Breast Disorders: Breast Cancer". Archived from the original on 2 October 2011. Retrieved 5 February 2008.
9. National Cancer Institute (27 June 2005). "Paget's Disease of the Nipple: Questions and Answers". Archived from the original on 10 April 2008. Retrieved 6 February 2008.
10. www.answers.com. "Oncology Encyclopedia: CystosarcomaPhyllodes". Archived from the original on 8 September 2010. Retrieved 10 August 2010.
11. Lacroix M, Significance, detection and markers of disseminated breast cancer cells, *Endocrine Related Cancer*, 2006; 13(4):1033-67.
12. Breast cancer. *emedicinehealth*. 2010. [20 Mar 2010]. [http://www.emedicinehealth.com/breast\\_cancer/page2\\_em.htm](http://www.emedicinehealth.com/breast_cancer/page2_em.htm).
13. Fletcher S. W. Patient information: Risk factor for breast cancer. Up-To-Date. 2008. Jan 29, [20 Mar 2010]. <http://www.utdol.com/patients/content/topic.do?topicKey=~rZvVFHbEjw>
14. Tiernan A. M. Behavioral risk factor in breast cancer: Can risk be modified, *Oncologist*, 2003; 8(4):326-334.
15. Definite breast cancer risks. CancerHelp UK. 2008. Sep 26, [20 Mar 2010]. <http://www.cancerhelp.org.uk/type/breast-cancer/about/risks/definite-breast-cancer-risks>.
16. Cavalieri E, Chakravarti D, Guttentplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T, Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention, *BiochimicaetBiophysicaActa*, 2006; 1766(1):63-78.
17. Haslam SZ, Woodward TL, Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland, *Breast Cancer Res*, 2003; 5(4):208-15.
18. Wiseman BS, Werb Z, Stromal effects on mammary gland development and breast cancer, *Science*, 2002; 296 (5570):1046-9.
19. Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F, Molecular mechanisms of leptin and adiponectin in breast cancer, *Eur. J. Cancer*, 2011; 47(1):33-43.
20. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF, A systematic review of genetic polymorphisms and breast cancer risk, *Cancer Epidemiology, Biomarkers & Prevention*, 1999; 8(10):843-54.
21. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL, Variation of breast cancer risk among BRCA1/2 carriers, *JAMA*, 2008; 299(2):194-201.
22. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR, Involvement of Brca2 in DNA repair, *Mol. Cell*, 1998; 1(3):347-57.
23. Marietta C, Thompson LH, Lamerdin JE, Brooks PJ, Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis, *Mutat. Res*, 2009; 664(1-2):77-83.
24. Theruvathu JA, Jaruga P, Nath RG, Dizdaroglu M, Brooks PJ, Polyamines stimulate the formation of mutagenic 1,N2-propanodeoxyguanosine adducts from acetaldehyde, *Nucleic Acids Res*, 2005; 33(11):3513-20.
25. Holly Yan (2013-05-14). "What's the gene that led to Angelina Jolie's double mastectomy?". *Health. CNN*.
26. "BRCA1 and BRCA2: Cancer Risk and Genetic Testing". National Cancer Institute. 29 May 2009.
27. Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, Palomares MR, Lowstuter KJ, MacDonald DJ, Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer, *Journal of the American Medical Association*, 2007; 297(23): 2587-2595.
28. Kurian AW, Sigal BM, Plevritis SK, Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers, *J ClinOncol*, 2010; 28(2): 222-31.
29. Fishman A, The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review, *Int. J. Gynecol. Cancer*, 2010; 20(11 Suppl 2):S31-3.
30. Pal T, Keefe D, Sun P, Narod SA, Fertility in women with BRCA mutations: a case-control study, *Fertil. Steril*, 2010; 93 (6):1805-8.
31. Broer S.L, Broekmans F. J. M., Laven, J. S. E, Fauser B. C. J. M, Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications, *Human Reproduction Update*, 2014; 20 (5):688-701.
32. Oktay K, Kim JY, Barad D, Babayev SN, Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks, *J ClinOncol*, 2010; 28 (2):240-4.
33. Moslehi R, Singh R, Lessner L, Friedman JM, Impact of BRCA mutations on female fertility and offspring sex ratio, *Am J Hum Biol*, 2010; 22 (2):201-5.
34. Balmaña, Judith; Díez, Orland; Campos, Berta; Majewski, Magdalena; Sanz, Judit; Alonso, Carmen; Baiget, Montserrat; Garber, Judy E, Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?, *Breast Cancer Research and Treatment*, 2005; 92 (3):273-277.
35. Agnese D M, Battle of the BRCA1/BRCA2 (offspring) sex ratios: truth or consequences, *Journal of Medical Genetics*, 2006; 43 (3):201-202.
36. Morris, Joi L.; Gordon, Ora K, Positive Results: Making the Best Decisions When You're at High Risk for Breast or Ovarian Cancer. Amherst, N.Y. Prometheus Books, 2010; ISBN 978-1-59102-776-8.
37. Kotsopoulos J, Lubinski J, Salmena L, et al., Breastfeeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers, *Breast Cancer Res*, 2012; 14 (2):R42.
38. Hamel PJ (2007-05-29). "BRCA1 and BRCA2: No Longer the Only Troublesome Genes Out There". *HealthCentral*. Retrieved 2010-07-02.
39. "OrthoMaM phylogenetic marker: BRCA2 coding sequence"
40. Duncan JA, Reeves JR, Cooke TG, BRCA1 and BRCA2 proteins: roles in health and disease, *Molecular Pathology*, 1998; 51 (5):237-47.

41. Yoshida K, Miki Y, Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage, *Cancer Science*, 2004; 95 (11): 866-71.
42. Check W (2006-09-01). "BRCA: What we know now". College of American Pathologists. Retrieved 2010-08-23.
43. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J, BASC a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures, *Genes Dev*, 2000; 14 (8):927-39.
44. Friedenson B, The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers, *BMC Cancer*, 2007; 7:152.
45. Starita LM, Parvin JD, The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair, *Current Opinion in Cell Biology*, 2003; 15 (3):345-350.
46. Cortez, D., Wang, Y., Qin, J., Elledge, S.J, Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks, *Science*, 1999; 286(5442):1162-1166.
47. National Center for Biotechnology Information, U.S. National Library of Medicine Entrez Gene reference information for BRCA1 breast cancer 1, early onset (Homo sapiens)
48. "Genetics". *Breastcancer.org*. 2012-09-17.
49. Mazoyer S, Genomic rearrangements in the BRCA1 and BRCA2 genes, *Hum. Mutat*, 2005; 25 (5):415-22.
50. Barrois M, Bièche I, Mazoyer S, Champème MH, Bressac-de Paillerets B, Lidereau R, Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families, *Clin. Genet*, 2004; 65 (2):131-6.
51. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijdt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G, Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method, *Cancer Res*, 2003; 63 (7):1449-53.
52. Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M, Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments, *Hum. Mutat*, 2002; 20 (3):218-26.
53. Rouleau E, Lefol C, Tozlu S, Andrieu C, Guy C, Copigny F, Nogues C, Bieche I, Lidereau R, High-resolution oligonucleotide array-CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1, *Clin. Genet*, 2007; 72 (3):199-207.
54. Tapia T, Smalley SV, Kohen P, Muñoz A, Solis LM, Corvalan A, Faundez P, Devoto L, Camus M, Alvarez M, Carvallo P, Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors, *Epigenetics*, 2008; 3(1):157-63.
55. Shen J, Ambrosone CB, Zhao H, Novel genetic variants in microRNA genes and familial breast cancer, *Int. J. Cancer*, 2009; 124 (5):1178-82.
56. Levin B, Lech D, Friedenson B, Evidence that BRCA1- or BRCA2-associated cancers are not inevitable, *Mol Med*, 2012; 18 (9):1327-37.
57. Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ, Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas, *Nat. Genet*, 1999; 21 (2):236-40.
58. Mueller CR, Roskelley CD, Regulation of BRCA1 expression and its relationship to sporadic breast cancer, *Breast Cancer Res*, 2003; 5 (1):45-52.
59. Jacinto FV, Esteller M, Mutator pathways unleashed by epigenetic silencing in human cancer, *Mutagenesis*, 2007; 22 (4):247-53.
60. Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G, miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition, *J. Natl. Cancer Inst*, 2013; 105 (22):1750-8.
61. McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, Wei JJ, Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma, *Mod. Pathol*, 2012; 25 (12):1644-53.
62. Brody LC, Biesecker BB, Breast cancer susceptibility genes. BRCA1 and BRCA2, *Medicine (Baltimore)*, 1998; 77 (3):208-26.
63. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM, Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas, *Clin Cancer Res*, 2014; 20(3):764-75.
64. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG, Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors, *J. Natl. Cancer Inst*, 2000; 92 (7):564-9.
65. "OrthoMaM phylogenetic marker: BRCA2 coding sequence"
66. Tavtigian, S.V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., et al., The complete BRCA2 gene and mutations in chromosome 13q linked kindreds, *Nat. Genet*, 1996; 12(3):333-337.
67. Chen, J.J., Silver, D., Cantor, S., Livingston, D.M., Scully, R., BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway, *Cancer Res*, 1999; 59 (7):1752-1756.
68. Lakhani, S.R., van de Vijver, M.J., Jacquemier, J., Anderson, T.J., Osin, P.P., McGuffog, L., Easton, D.F., The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2, *J. Clin. Oncol*, 2002; 20(9):2310-2318.
69. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13, *Science*, 1994; 265 (5181):2088-90.
70. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2, *Mol. Cell*, 2006; 22 (6):719-29.
71. Buisson R, Dion-Côté AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY, Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination, *Nature Structural & Molecular Biology*, 2010; 17(10):1247-54.
72. Mijic, Sofija; Zellweger, Ralph; Chappidi, Nagaraja; Berti, Matteo; Jacobs, Kurt; Mutreja, Karun; Ursich, Sebastian; Chaudhuri, Arnab Ray; Nussenzweig, Andre, Replication fork reversal triggers fork degradation in BRCA2-defective cells, *Science*, 2017; 8(1).
73. Holloman WK, Unraveling the mechanism of BRCA2 in homologous recombination, *Nat. Struct. Mol. Biol*, 2011; 18 (7):748-54.
74. Chun J, Buechelmaier ES, Powell SN, Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway, *Mol. Cell. Biol*, 2013; 33 (2):387-95.
75. Egawa C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S, High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients, *Int. J. Cancer*, 2002; 98 (6):879-82.
76. <https://en.wikipedia.org/wiki/BRCA1>
77. <https://en.wikipedia.org/wiki/BRCA2>